

# Satellite Symposium 3

---

## Chairperson

---

**Bom Taeck Kim**  
Ajou University, Korea

---

## Speaker

---

**Jung Hwan Park**  
Hanyang University, Korea



## Jung Hwan Park

Hanyang University, Korea

### • Education

Period	Affiliation	Position
– 2022	Washington University in St Louis	Visiting Scholar
– 2014	Yonsei University College of Medicine	M.D., Ph.D.
– 2011	Yonsei University College of Medicine	B.S.
– 2006	Yonsei University College of Medicine	M.D.

### • Affiliations / Experience

Period	Affiliation	Position
– 2023-Present	The Catholic University of Korea	Associate Professor
– 2019-2022	The Catholic University of Korea	Assistant Professor
– 2015-2018	Yonsei University College of Medicine	Clinical Assistant Professor
– 2011-2014	Yonsei University College of Medicine	Research Fellow
– 2007-2011	Yonsei University College of Medicine	Residency

### • Committee Memberships

- Korean Diabetes Association
- Korean Endocrine Society
- Korean Society for the Study of Obesity

### • Publications

- Lee EY, Hughes JW. Rediscovering Primary Cilia in Pancreatic Islets. *Diabetes Metab J* 2023 Apr 28
- Kim WJ, Lee SJ, Lee E, Lee EY, Han K. Risk of Incident Dementia According to Glycemic Status and Comorbidities of Hyperglycemia: A Nationwide Population-Based Cohort Study. *Diabetes Care* 2022;45:134–141
- Kim MJ, Lee EY, You YH, Yang HK, Yoon KH, Kim JW. Generation of iPSC-derived insulin-producing cells from patients with type 1 and type 2 diabetes compared with healthy control. *Stem Cell Res.* 2020 Oct;48:101958
- Lee EY, Han K, Kim DH, Park YM, Kwon HS, Yoon KH, Kim MK, Lee SH. Exposure-weighted scoring for metabolic syndrome and the risk of myocardial infarction and stroke: a nationwide population-based study. *Cardiovasc Diabetol.* 2020 Sep 29;19(1):153
- Lee EY, Lee YH, Yi SW, Shin SA, Yi JJ. BMI and All-Cause Mortality in Normoglycemia, Impaired Fasting Glucose, Newly Diagnosed Diabetes, and Prevalent Diabetes: A Cohort Study. *Diabetes Care.* 2017 Aug;40(8):1026-1033

**Satellite Symposium 3**

## **Clinical Value of EPA (Icosapentate Ethyl)**

Jung Hwan Park (Hanyang University, Korea)

---

Eicosapentaenoic acid (EPA), an omega-3 fatty acid predominantly found in fish oils, has garnered significant attention for its clinical benefits across a range of health conditions. This lecture reviews the current evidence regarding the clinical value of EPA, focusing on its impact on cardiovascular health. Clinical studies have demonstrated that EPA can effectively reduce triglyceride levels, contributing to a decreased risk of cardiovascular events. Additionally, its anti-inflammatory properties have shown promise in managing conditions such as rheumatoid arthritis and inflammatory bowel disease. Emerging research also suggests that EPA may offer neuroprotective effects, potentially benefiting patients with depression and cognitive decline. While the therapeutic potential of EPA is supported by a growing body of evidence, further research is needed to refine dosage recommendations and elucidate mechanisms of action. Overall, EPA represents a valuable adjunct in the management of various clinical conditions, underscoring the need for continued exploration into its optimal use in clinical practice.